Director Segal reports holdings in Aktis Oncology (AKTS) Form 3 filing

Rhea-AI Filing Summary

Aktis Oncology director Lloyd Mitchell Segal filed an initial Form 3 reporting his equity interests as of January 8, 2026. Indirect holdings include 13,142 shares of Series A Redeemable Convertible Preferred Stock and 6,489 shares of Series B Redeemable Convertible Preferred Stock held by Arvala, Inc., where he is president and sole stockholder and may share voting and dispositive power. Each preferred share is convertible into common stock on a 3.8044-for-1 basis and will automatically convert to common stock immediately before the closing of Aktis Oncology’s initial public offering. He also reports several stock options for common stock, including grants covering 32,856, 31,542, 6,571, 10,514 and 18,933 shares at exercise prices ranging from $1.45 to $18.00, with one grant fully vested and others vesting monthly or in full on January 8, 2027 subject to continued service.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Segal Lloyd Mitchell

(Last) (First) (Middle)

C/O AKTIS ONCOLOGY, INC.

17 DRYDOCK AVENUE, SUITE 17-401

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/08/2026

3. Issuer Name and Ticker or Trading Symbol
Aktis Oncology, Inc. [ AKTS ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series A Redeemable Convertible Preferred Stock	(1)	(1)	Common Stock	13,142	(1)	I	See Footnote(3)
Series B Redeemable Convertible Preferred Stock	(2)	(2)	Common Stock	6,489	(2)	I	See Footnote(3)
Stock Option (Right to Buy)	(4)	02/21/2031	Common Stock	32,856	$1.45	D
Stock Option (Right to Buy)	(5)	11/15/2032	Common Stock	31,542	$3.66	D
Stock Option (Right to Buy)	(6)	06/30/2034	Common Stock	6,571	$4.95	D
Stock Option (Right to Buy)	(7)	12/09/2034	Common Stock	10,514	$10.66	D
Stock Option (Right to Buy)	(8)	01/07/2036	Common Stock	18,933	$18	D

Explanation of Responses:

1. Each share of Series A Redeemable Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 3.8044-for-1 basis and have no expiration date. All shares of Series A Redeemable Convertible Preferred Stock will automatically convert on a 3.8044-for-1 basis into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

2. Each share of Series B Redeemable Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 3.8044-for-1 basis and have no expiration date. All shares of Series B Redeemable Convertible Preferred Stock will automatically convert on a 3.8044-for-1 basis into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

3. Consists of 13,142 shares of Series A Redeemable Convertible Preferred Stock and 6,489 shares of Series B Redeemable Convertible Preferred Stock held by Arvala, Inc.(f/k/a 3996953 Canada Inc.). The Reporting Person is the president and sole stockholder of Arvala, Inc. and may be deemed to share the voting and dispositive power over the shares held by Arvala, Inc.

4. These options have vested in full.

5. 25% of the original number of shares subject to the option vested on November 1, 2023, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.

6. Beginning on January 1, 2024, 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments, subject to the Reporting Person's continuous service through each vesting date, inclusive.

7. Beginning on October 9, 2024, 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments, subject to the Reporting Person's continuous service through each vesting date, inclusive.

8. The number of shares subject to the option shall vest in full on January 8, 2027, subject to the Reporting Person's continuous service through such vesting date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Lloyd Mitchell Segal	01/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the AKTS Form 3 filed by Lloyd Mitchell Segal show?

The Form 3 reports Lloyd Mitchell Segal’s status as a director of Aktis Oncology, Inc. and discloses his indirect preferred share holdings via Arvala, Inc. along with several stock option awards for common stock.

How many preferred shares linked to Aktis Oncology (AKTS) are held via Arvala, Inc.?

Arvala, Inc. holds 13,142 shares of Series A Redeemable Convertible Preferred Stock and 6,489 shares of Series B Redeemable Convertible Preferred Stock. Segal is Arvala’s president and sole stockholder and may be deemed to share voting and dispositive power over these shares.

How are the Series A and Series B preferred shares in AKTS convertible?

Each share of Series A and Series B Redeemable Convertible Preferred Stock is convertible into Aktis Oncology common stock on a 3.8044-for-1 basis and has no expiration date. All such preferred shares will automatically convert into common stock immediately prior to the closing of the company’s initial public offering.

What stock options for Aktis Oncology common stock does Lloyd Mitchell Segal report?

Segal reports multiple stock options (rights to buy) for Aktis Oncology common stock, including grants for 32,856, 31,542, 6,571, 10,514, and 18,933 shares with exercise prices of $1.45, $3.66, $4.95, $10.66, and $18.00, respectively.

What are the key vesting terms of Lloyd Mitchell Segal’s AKTS stock options?

One option grant has vested in full. Another vested 25% on November 1, 2023 with the remainder vesting in equal monthly installments. Additional grants vest in monthly installments beginning January 1, 2024 and October 9, 2024, and one grant vests in full on January 8, 2027, all subject to Segal’s continuous service.

Is the Aktis Oncology Form 3 a new transaction or a holdings report?

This Form 3 is an initial statement of beneficial ownership, listing Lloyd Mitchell Segal’s existing indirect preferred share holdings via Arvala, Inc. and his stock options, rather than reporting new purchase or sale transactions.